XOMA Corp (XOMA) Given Average Rating of “Hold” by Brokerages

Share on StockTwits

Shares of XOMA Corp (NASDAQ:XOMA) have received a consensus rating of “Hold” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and two have given a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $26.13.

Several analysts have recently issued reports on the company. TheStreet cut XOMA from a “c-” rating to a “d-” rating in a research note on Monday, November 26th. ValuEngine upgraded XOMA from a “sell” rating to a “hold” rating in a research note on Tuesday, December 11th. HC Wainwright set a $36.00 price objective on XOMA and gave the company a “buy” rating in a research note on Wednesday, November 7th. Finally, Cowen reiterated a “hold” rating on shares of XOMA in a research note on Thursday, November 8th.

In other XOMA news, major shareholder Bvf Partners L. P/Il bought 2,810 shares of the company’s stock in a transaction that occurred on Wednesday, December 12th. The shares were purchased at an average price of $14.75 per share, with a total value of $41,447.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Bvf Partners L. P/Il bought 21,141 shares of the company’s stock in a transaction that occurred on Thursday, November 15th. The stock was acquired at an average cost of $13.31 per share, for a total transaction of $281,386.71. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 380,177 shares of company stock worth $5,476,116. Insiders own 7.90% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. increased its holdings in XOMA by 12.4% in the fourth quarter. BlackRock Inc. now owns 508,672 shares of the biotechnology company’s stock valued at $6,434,000 after buying an additional 56,130 shares during the last quarter. Fosun International Ltd purchased a new position in shares of XOMA during the fourth quarter worth about $3,842,000. Vanguard Group Inc grew its holdings in shares of XOMA by 1.0% during the third quarter. Vanguard Group Inc now owns 311,093 shares of the biotechnology company’s stock worth $5,466,000 after purchasing an additional 3,167 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of XOMA by 1.0% during the third quarter. Vanguard Group Inc. now owns 311,093 shares of the biotechnology company’s stock worth $5,466,000 after purchasing an additional 3,167 shares during the last quarter. Finally, Acadian Asset Management LLC grew its holdings in shares of XOMA by 6.0% during the third quarter. Acadian Asset Management LLC now owns 101,820 shares of the biotechnology company’s stock worth $1,789,000 after purchasing an additional 5,769 shares during the last quarter. 42.44% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:XOMA traded up $0.13 during trading hours on Friday, reaching $12.20. 59,382 shares of the stock were exchanged, compared to its average volume of 48,365. The company has a quick ratio of 5.38, a current ratio of 5.38 and a debt-to-equity ratio of 19.16. XOMA has a twelve month low of $11.02 and a twelve month high of $29.29. The stock has a market capitalization of $102.36 million, a price-to-earnings ratio of 12.45 and a beta of 2.43.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.40). The company had revenue of $0.90 million during the quarter, compared to analyst estimates of $0.83 million. XOMA had a negative net margin of 129.85% and a negative return on equity of 267.64%. On average, sell-side analysts expect that XOMA will post -1.73 EPS for the current fiscal year.

About XOMA

XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.

Further Reading: How Investors Can Profit from Options Trading

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply